Pfeiffer, Sebastian

[["dc.bibliographiccitation.firstpage","900"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","906"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Götze, Katharina S."],["dc.contributor.author","Müller-Thomas, Catharina"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Brümmendorf, Tim H."],["dc.contributor.author","Bug, Gesine"],["dc.contributor.author","Ottmann, Oliver G."],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Stadler, Michael"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Blau, Igor W."],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Metz, Michael"],["dc.contributor.author","Detken, Sven"],["dc.contributor.author","Seraphin, Jörg"],["dc.contributor.author","Jentsch-Ullrich, Kathleen"],["dc.contributor.author","Böhme, Angelika"],["dc.contributor.author","Schmidt, Burkhard C."],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T09:22:10Z"],["dc.date.available","2018-11-07T09:22:10Z"],["dc.date.issued","2013"],["dc.description.abstract","The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM) metaphases. Most aberrations can also be detected by fluorescence-in situ-hybridization (FISH). For this prospective multicenter German diagnostic study (www.clinicaltrials.gov: #NCT01355913) 360 patients, as yet, were followed up to 3 years by sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood (PB) cells using comprehensive FISH probe panels, resulting in a total number of 19,516 FISH analyses. We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB. (C) 2013 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Celgene(R) Germany"],["dc.identifier.doi","10.1016/j.leukres.2013.03.019"],["dc.identifier.isi","000321111900012"],["dc.identifier.pmid","23623559"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29278"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0145-2126"],["dc.title","Molecular cytogenetic monitoring from CD34+peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","JDDG Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Brehmer, Franziska"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Daeschlein, G."],["dc.contributor.author","Ahmed, R."],["dc.contributor.author","Pfeiffer, S."],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Simon, D."],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Wandke, Dirk"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T09:19:10Z"],["dc.date.available","2018-11-07T09:19:10Z"],["dc.date.issued","2013"],["dc.format.extent","10"],["dc.identifier.isi","000324332500029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28574"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.title","The Treatment of chronic venous Leg Ulcers with direct Plasma (PlasmaDerm (R) VU 2010): Results of a single center, two-arm, open-label, randomized, controlled Trial"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","589"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","600"],["dc.bibliographiccitation.volume","265"],["dc.contributor.author","Hasan, Alkomiet"],["dc.contributor.author","Wolff-Menzler, Claus"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Weidinger, Elif"],["dc.contributor.author","Jobst, Andrea"],["dc.contributor.author","Hoell, Imke"],["dc.contributor.author","Malchow, Berend"],["dc.contributor.author","Yeganeh-Doost, Peyman"],["dc.contributor.author","Strube, Wolfgang"],["dc.contributor.author","Quast, Silke"],["dc.contributor.author","Mueller, Norbert"],["dc.contributor.author","Wobrock, Thomas"],["dc.date.accessioned","2018-11-07T09:51:15Z"],["dc.date.available","2018-11-07T09:51:15Z"],["dc.date.issued","2015"],["dc.description.abstract","Despite many pharmacological and psychosocial treatment options, schizophrenia remains a debilitating disorder. Thus, new treatment strategies rooted in the pathophysiology of the disorder are needed. Recently, vagus nerve stimulation (VNS) has been proposed as a potential treatment option for various neuropsychiatric disorders including schizophrenia. The objective of this study was to investigate for the first time the feasibility, safety and efficacy of transcutaneous VNS in stable schizophrenia. A bicentric randomized, sham-controlled, double-blind trial was conducted from 2010 to 2012. Twenty schizophrenia patients were randomly assigned to one of two treatment groups. The first group (active tVNS) received daily active stimulation of the left auricle for 26 weeks. The second group (sham tVNS) received daily sham stimulation for 12 weeks followed by 14 weeks of active stimulation. Primary outcome was defined as change in the Positive and Negative Symptom Scale total score between baseline and week 12. Various other secondary measures were assessed to investigate safety and efficacy. The intervention was well tolerated with no relevant adverse effects. We could not observe a statistically significant difference in the improvement of schizophrenia psychopathology during the observation period. Neither psychopathological and neurocognitive measures nor safety measures showed significant differences between study groups. Application of tVNS was well tolerated, but did not improve schizophrenia symptoms in our 26-week trial. While unsatisfactory compliance questions the feasibility of patient-controlled neurostimulation in schizophrenia, the overall pattern of symptom change might warrant further investigations in this population."],["dc.description.sponsorship","CerboMed GmbH, Erlangen, Germany"],["dc.identifier.doi","10.1007/s00406-015-0618-9"],["dc.identifier.isi","000361397100006"],["dc.identifier.pmid","26210303"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35876"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","1433-8491"],["dc.relation.issn","0940-1334"],["dc.title","Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","148"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of the European Academy of Dermatology and Venereology"],["dc.bibliographiccitation.lastpage","155"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Brehmer, Franziska"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.contributor.author","Daeschlein, G."],["dc.contributor.author","Ahmed, R."],["dc.contributor.author","Pfeiffer, S."],["dc.contributor.author","Goerlitz, Anke"],["dc.contributor.author","Simon, D."],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Wandke, Dirk"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T10:04:03Z"],["dc.date.available","2018-11-07T10:04:03Z"],["dc.date.issued","2015"],["dc.description.abstract","BackgroundCold atmospheric plasma (CAP, i.e. ionized air) is an innovating promising tool in reducing bacteria. ObjectiveWe conducted the first clinical trial with the novel PlasmaDerm((R)) VU-2010 device to assess safety and, as secondary endpoints, efficacy and applicability of 45s/cm(2) cold atmospheric plasma as add-on therapy against chronic venous leg ulcers. MethodsFrom April 2011 to April 2012, 14 patients were randomized to receive standardized modern wound care (n=7) or plasma in addition to standard care (n=7) 3x per week for 8weeks. The ulcer size was determined weekly (Visitrak((R)), photodocumentation). Bacterial load (bacterial swabs, contact agar plates) and pain during and between treatments (visual analogue scales) were assessed. Patients and doctors rated the applicability of plasma (questionnaires). ResultsThe plasma treatment was safe with 2 SAEs and 77 AEs approximately equally distributed among both groups (P=0.77 and P=1.0, Fisher's exact test). Two AEs probably related to plasma. Plasma treatment resulted in a significant reduction in lesional bacterial load (P=0.04, Wilcoxon signed-rank test). A more than 50% ulcer size reduction was noted in 5/7 and 4/7 patients in the standard and plasma groups, respectively, and a greater size reduction occurred in the plasma group (plasma -5.3cm(2), standard: -3.4cm(2)) (non-significant, P=0.42, log-rank test). The only ulcer that closed after 7weeks received plasma. Patients in the plasma group quoted less pain compared to the control group. The plasma applicability was not rated inferior to standard wound care (P=0.94, Wilcoxon-Mann-Whitney test). Physicians would recommend (P=0.06, Wilcoxon-Mann-Whitney test) or repeat (P=0.08, Wilcoxon-Mann-Whitney test) plasma treatment by trend. ConclusionCold atmospheric plasma displays favourable antibacterial effects. We demonstrated that plasma treatment with the PlasmaDerm((R)) VU-2010 device is safe and effective in patients with chronic venous leg ulcers. Thus, larger controlled trials and the development of devices with larger application surfaces are warranted."],["dc.identifier.doi","10.1111/jdv.12490"],["dc.identifier.isi","000346733800024"],["dc.identifier.pmid","24666170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38612"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1468-3083"],["dc.relation.issn","0926-9959"],["dc.title","Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm (R) VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Ophthalmology Retina"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Klingelhöfer, Anthea"],["dc.contributor.author","Mielke, Dorothee"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Striebe, Nina-Antonia"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Koscielny, Juergen"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2021-06-01T10:49:52Z"],["dc.date.available","2021-06-01T10:49:52Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1016/j.oret.2021.04.013"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86440"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","2468-6530"],["dc.title","Risk factors for Severe Bleeding Complications in Vitreoretinal Surgery and the Role of Antiplatelet or Anticoagulant Agents"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e11911"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","JMIR Research Protocols"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Nühnen, Viktoria P"],["dc.contributor.author","Pfützner, Wolfgang"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Laubach, Hans-Joachim"],["dc.contributor.author","Boehncke, Wolf-Henning"],["dc.contributor.author","Liebmann, Joerg"],["dc.contributor.author","Born, Matthias"],["dc.contributor.author","Schön, Michael P"],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2020-12-10T18:43:05Z"],["dc.date.available","2020-12-10T18:43:05Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.2196/11911"],["dc.identifier.eissn","1929-0748"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78189"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","923"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Graefe s Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","934"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Bretag, Mirko"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Goldammer, Lena"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2018-11-07T10:24:17Z"],["dc.date.available","2018-11-07T10:24:17Z"],["dc.date.issued","2017"],["dc.description.abstract","Purpose To evaluate prospectively the efficacy and safety of a fixed bimonthly ranibizumab treatment regimen (RABIMO) in eyes with neovascular age-related macular degeneration (nAMD) and to compare these results with a pro re nata (PRN) treatment scheme. Methods This was a 12-month, phase IV, single center, randomised, non-inferiority study. Following three initial monthly injections, patients were randomised to receive either ranibizumab bimonthly (RABIMO group) or ranibizumab PRN (PRN group) (n = 20 each). Main outcome measures were best-corrected visual acuity (BCVA), central retinal thickness (CRT), number of injections, and adverse events (AEs). Results BCVA [median (interquartile range, IQR)] increased significantly in both groups after 12 months [RABIMO group +8.5 (14); PRN group +6.5 (16) ETDRS letters] when compared to baseline (p < 0.0001; p = 0.0085). At month 12, the RABIMO treatment regimen was non-inferior to the PRN scheme (Delta BCVA = 3.5 ETDRS letters; p < 0.0001). CRT was significantly reduced in both groups after the 12-month study period (p < 0.0001 each), with no significant difference between groups (p = 0.6772). Number of overall injections [median (IQR)] was 8 (0) in the RABIMO versus 4 (5) in the PRN group (p = 0.0037). Three patients in the RABIMO group received one additional unscheduled injection. We observed no significant differences between groups in the number of patients with reported SAEs/AEs (RABIMO group n = 6/15; PRN group n = 7/13) (p = 0.7357/p = 0.4902). Conclusions We found no evidence of significant functional or anatomical differences between the RABIMO and PRN treatment regimens. However, the RABIMO group's number of injections was twice as high as the PRN group's (protocol-driven). In light of potential side effects, the fixed bimonthly treatment regimen might not be advisable for routine clinical care, but it might be a worthwhile treatment option if monthly monitoring is not possible. Eudra-CT number: 2009-017324-11."],["dc.description.sponsorship","Novartis Pharma GmbH, Germany"],["dc.identifier.doi","10.1007/s00417-017-3589-x"],["dc.identifier.isi","000401436500008"],["dc.identifier.pmid","28102456"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42627"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1435-702X"],["dc.relation.issn","0721-832X"],["dc.title","Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Silling, Gerda"],["dc.contributor.author","Wilhelm, Christian"],["dc.contributor.author","Zeis, Matthias"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Schmitz, Norbert"],["dc.date.accessioned","2018-11-07T09:10:20Z"],["dc.date.available","2018-11-07T09:10:20Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009803810"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26463"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","961"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Graefe's Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","969"],["dc.bibliographiccitation.volume","258"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Striebe, Nina Antonia"],["dc.contributor.author","Khattab, Mohammed Haitham"],["dc.contributor.author","Affeldt, Johannes"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2020-12-10T14:10:35Z"],["dc.date.available","2020-12-10T14:10:35Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00417-019-04554-1"],["dc.identifier.eissn","1435-702X"],["dc.identifier.issn","0721-832X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70806"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Risk of perioperative bleeding complications in rhegmatogenous retinal detachment surgery: a retrospective single-center study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1559"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Graefe's Archive for Clinical and Experimental Ophthalmology"],["dc.bibliographiccitation.lastpage","1564"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Lahme, Eva"],["dc.contributor.author","van Oterendorp, Christian"],["dc.contributor.author","Khattab, Mohammed"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Kulanga, Miroslav"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2018-10-08T09:22:04Z"],["dc.date.available","2018-10-08T09:22:04Z"],["dc.date.issued","2017-08"],["dc.description.abstract","To identify factors that may lead to a rapid progression in macula-on rhegmatogenous retinal detachment (RRD), in particular, those that may lead to macular involvement.Observational, prospective, single-center study. Patients referred for surgery due to primary rhegmatogenous retinal detachment with the macula on between 2009 and 2013 were included. Relevant factors analyzed included age, time delay until surgery, lens status, myopia, the detachment’s location and configuration as well as number, size and type of retinal breaks. Eyes underwent optical coherence tomography to detect macular detachment. A multivariate analysis was performed to investigate the effect of several factors in the progression of retinal detachment. A total of 116 eyes of 116 patients were included. Mean time delay between admission and surgery was 1.8 ± 1.4 days. Progression was observed in 19.8% of the eyes. Of those, 47.8% presented macular detachment. Ten of the 11 (90.9%) eyes presenting progression involving the macula also exhibited a bullous configuration, which was the only parameter that correlated significantly with detachment progression in patients with (p = 0.0036) and without (p = 0.0014) macular involvement. For the first time in a prospective trial, a bullous configuration was found to be a highly significant predictor for progression in macula-on detachments. Our data support prompt surgery in patients diagnosed with bullous macula-on RRD."],["dc.fs.pkfprnr","5911"],["dc.identifier.doi","10.1007/s00417-017-3696-8"],["dc.identifier.fs","627411"],["dc.identifier.pmid","28551879"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15876"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1435-702X"],["dc.title","Risk of progression in macula-on rhegmatogenous retinal detachment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]